arrow
V

Valentina Gambardella

university of valenci a
H指数:25
被引数:2,594

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical performance of tumor-informed versus tumor-agnostic ctDNA assays for colorectal cancer recurrence: A systematic review and diagnostic accuracy meta-analysis

基于肿瘤信息的循环肿瘤DNA检测与肿瘤无特异性循环肿瘤DNA检测在结直肠癌复发中的临床表现:一项系统评价和诊断准确性Meta分析

2025-12-070
OAAI
Brief Report: Emphysema as a prognostic factor in advanced NSCLC patients with COPD receiving immune checkpoint inhibitors.

简报:肺气肿作为合并COPD的晚期NSCLC患者接受免疫检查点抑制剂治疗时的预后因素。

2025-10-210
OAAI
Enhancing precision oncology: the role of molecular tumor boards in early identification and targeted treatment of ESCAT II-III alterations

增强精准肿瘤学:分子肿瘤委员会在早期识别和靶向治疗ESCAT II-III改变中的作用

2025-09-240
PREAI
Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374)

安全性概述及inavolisib单药和联合疗法在PIK3CA突变、HR阳性、HER2阴性晚期乳腺癌中的管理(GO39374)

2025-07-010
PRE
Whole-exome tumor-agnostic ctDNA analysis enhances minimal residual disease detection and reveals relapse mechanisms in localized colon cancer

全外显子组肿瘤非特异性ctDNA分析增强了局部结直肠癌微小残留病灶的检测,并揭示了其复发机制

2025-04-290
OA
Decoding chromosomal instability insights in CRC by integrating omics and patient-derived organoids

通过整合组学和患者源性类器官解码结直肠癌中的染色体不稳定性见解

2025-02-280
OA
ctDNA whole exome sequencing in pancreatic ductal adenocarcinoma unveils organ-dependent metastatic mechanisms and identifies actionable alterations in fast progressing patients
2024-09-011
PRE
Trial in progress: A phase I, open-label, multicenter study of ZL-1218, an anti-CCR8 IgG1, as a single agent and as combination therapy with anti-PD-1 antibody to evaluate the safety, tolerability, and pharmacokinetics in subjects with advanced solid tumor
2024-04-050
PRE
Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure

第一阶段,TYRP1-TCB的首次人体研究 (RO7293583),一种新型TYRP1-targeting CD3 T细胞接合器,用于转移性黑色素瘤: 主动药物监测以评估免疫反应对药物暴露的影响

2024-03-212
OAAI
Trials in progress: a global phase 1/1b clinical trial evaluating exarafenib (KIN-2787), a highly selective pan-RAF inhibitor, in adult patients with BRAF-altered solid tumors and NRAS mutant melanoma
2023-04-145
PRE
Safety and anti-tumor activity of a novel Treg depleter RG6292, as a single agent and in combination with atezolizumab in patients with solid tumors
2023-04-142
PRE
Pharmacokinetic/pharmacodynami c (PK/PD) relationships of the novel Treg depleter RG6292 in Phase Ia and Ib studies in patients with solid tumors
2023-04-142
PRE
Genomic analysis of circulating tumor DNA (ctDNA) from patients with HR+, HER2-mutant metastatic breast cancer (MBC) enrolled in SUMMIT: mechanisms of acquired resistance to neratinib plus fulvestrant plus trastuzumab (N plus F plus T)
2023-03-010
PRE
Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction

用于药物敏感性预测的晚期结直肠癌患者衍生的类器官的蛋白质转录组学分析

2023-01-0629
OAAI
Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma
2022-10-173
OA
A phase I/Ib study of inavolisib (GDC-0077) in combination with fulvestrant in patients (pts) with PIK3CA-mutated hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer
2022-02-153
PRE